Table 1.
Resistance mechanisms underlying cefotaxime resistance in 91 Enterobacteriaceae isolates from bloodstream infections (BSI), Cambodia
| ESBL (n = 88) | TEM | SHV | OXA-1/30 | No. of isolates | + pAmpC | CipSMXGef | E. coli ST131 | |
|---|---|---|---|---|---|---|---|---|
| CTX-M-1 group (n = 50)1 | ||||||||
| CTX-M-15 (n = 41) | − | − | + | 18 | 1 (CMY-2-like) | 15 | 2 | |
| + | − | − | 6 | − | 3 | − | ||
| + | − | + | 9 | − | 8 | 1 | ||
| + | + | + | 5 | − | 4 | − | ||
| − | − | − | 2 | 1 (CMY-2-like) | 0 | − | ||
| + | + | − | 1 | − | 1 | − | ||
| CTX-M-55 (n = 7) | + | − | − | 6 | 1 (CMY-2-like) | 5 | − | |
| − | − | − | 1 | − | 1 | − | ||
| CTX-M-3 (n = 2) | + | − | − | 1 | − | 1 | − | |
| + | + | − | 1 | − | 0 | − | ||
| CTX-M-9 group (n = 30)b | ||||||||
| CTX-M-14 (n = 21) | + | − | − | 8 | − | 6 | 4 | |
| − | − | − | 8 | − | 5 | 7 | ||
| + | + | − | 3 | − | 0 | − | ||
| − | + | − | 1 | − | 0 | − | ||
| − | − | + | 1 | − | 0 | − | ||
| CTX-M-27 (n = 9) | + | − | − | 4 | − | 2 | 1 | |
| − | − | − | 4 | − | 1 | 3 | ||
| + | + | − | 1 | − | 0 | − | ||
| CTX-M-1 + M-9 group (n = 6)c | ||||||||
| CTX-M-15 + CTX-M-14 (n = 2) | + | + | − | 1 | 1 (DHA) | 1 | − | |
| − | − | + | 1 | − | 0 | − | ||
| CTX-M-15 + CTX-M-27 (n = 3) | − | − | + | 1 | − | 1 | − | |
| − | − | − | 1 | − | 0 | − | ||
| + | − | + | 1 | − | 1 | − | ||
| CTX-M-3 + CTX-M-27 (n = 1) | + | + | − | 1 | − | 0 | − | |
| Non-CTX-M ESBL (n = 2)d | + | + | − | 1 | − | 0 | − | |
| − | + | − | 1 | − | 0 | − | ||
| Non-ESBL (n = 3)e | + | − | − | 1 | 1 (CMY-2-like) | 0 | − | |
| + | + | + | 1 | 1 (DHA) | 0 | − | ||
| + | + | − | 1 | − | 0 | − |
aIncludes E. coli (n = 39), K. pneumoniae (n = 6) and Enterobacter spp. (n = 5)
bIncludes E. coli (n = 25) and K. pneumoniae (n = 5)
cIncludes E. coli (n = 3) and K. pneumoniae (n = 2) and Enterobacter spp. (n = 1)
dIncludes K. pneumoniae (n = 3)
eIncludes E. coli (n = 1) and K. pneumoniae (n = 1)
f CipSMXGe combined resistance to cefotaxime, ciprofloxacin (Cip), SMX-TMP (SMX) and gentamicin (Ge)